We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Manganese-Enhanced Magnetic Resonance Imaging of the Myocardium

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03607669
Recruitment Status : Unknown
Verified May 2018 by University of Edinburgh.
Recruitment status was:  Recruiting
First Posted : July 31, 2018
Last Update Posted : July 31, 2018
Information provided by (Responsible Party):
University of Edinburgh

Brief Summary:

Scanning the heart using magnetic resonance imaging (MRI) enables detailed assessment of its structure and function. MRI can give more detailed information about the heart by using a contrast 'dye' that is injected into a vein during the scan. This can highlight abnormal areas within the heart. Current contrast dyes help identify scarring within the heart, which is useful in people who have had heart attacks. The investigators plan to test new contrast dye containing manganese, which works differently to current agents. They believe it will provide unique insight into how the heart works.

There are many different causes of heart problems and the investigators plan to use this new contrast agent to scan three patient groups; (i) heart disease caused by heart attacks, (ii) heart disease with abnormal thickening of the heart muscle, and (iii) heart disease where the heart becomes stretched and enlarged. Healthy volunteers will be scanned for comparison.

The study will be carried out at the Royal Infirmary of Edinburgh. Adults between 18 and 65 with stable heart failure can be considered. Women who may be pregnant are unable to participate, as is anyone who has some types of metal in their body, as these people can't have an MRI scan safely. All participants will have 2 MRI scans lasting about an hour each, at least 2 days apart. Some participants will be have 4 MRI scans, over a longer time period. The investigators will also take some blood samples and record a tracing of the heart rhythm and will ensure there are no abnormal side-effects by telephone follow up.

The investigators believe this new agent has potential to better measure disease in the heart, improve the ability to establish the cause of heart disease and help monitor the disease over time as well as guide future treatment for individual patients.

Condition or disease Intervention/treatment
Ischemic Cardiomyopathy Dilated Cardiomyopathy Hypertrophic Cardiomyopathy Other: Mangafodipir trisodium

Layout table for study information
Study Type : Observational
Estimated Enrollment : 90 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Manganese-Enhanced Magnetic Resonance Imaging: Applications in Cardiomyopathy
Actual Study Start Date : June 1, 2018
Estimated Primary Completion Date : July 31, 2019
Estimated Study Completion Date : December 31, 2019

Group/Cohort Intervention/treatment
Healthy Controls
Healthy volunteers of similar age and gender
Other: Mangafodipir trisodium
Manganese-based MRI contrast agent

Ischaemic Cardiomyopathy
Patients with ischaemic cardiomyopathy and NYHA II-III heart failure
Other: Mangafodipir trisodium
Manganese-based MRI contrast agent

Hypertrophic Cardiomyopathy
Patients with hypertrophic cardiomyopathy and NYHA II-III heart failure
Other: Mangafodipir trisodium
Manganese-based MRI contrast agent

Dilated Cardiomyopathy
Patients with dilated cardiomyopathy and NYHA II-III heart failure
Other: Mangafodipir trisodium
Manganese-based MRI contrast agent

Primary Outcome Measures :
  1. Myocardial calcium-handling [ Time Frame: 1 year ]
    Quantification of myocardial calcium handling by T1 mapping, in healthy controls, and patient groups.

Secondary Outcome Measures :
  1. Myocardial infarction quantification [ Time Frame: 1 year ]
    Quantification of infarct size using manganese, and comparison with Gadolinium enhanced MRI.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients attending the Edinburgh Heart Centre will be invited to participate. Inpatients and outpatients are eligible. Healthy volunteers will be invited to participate by local recruitment.

Inclusion Criteria:

All subjects to be entered must:

  • ≥ 18 years of age
  • if female, be non-pregnant as evidenced by a urine pregnancy test or post-menopausal or surgically sterile
  • provide written informed consent after having received oral and written information about the study

Additionally, cohort-specific inclusion criteria as follows:

Healthy Volunteers

• Healthy adult with no known pre-existing medical conditions

Ischaemic Cardiomyopathy

  • Ischaemic cardiomyopathy as diagnosed by reduced LV ejection fraction (≤40%) secondary to one or more ischaemic events
  • Angiographically demonstrated LMS, LAD disease, or ≥2 vessel disease
  • NHYA class I-III heart failure, with stable symptoms not requiring change to diuretic therapy in the preceding month

Dilated Cardiomyopathy

  • Dilated cardiomyopathy characterised with echocardiography by reduced left ventricular systolic function with impaired systolic function (ejection fraction <40%).
  • NHYA class I-III heart failure, with stable symptoms not requiring change to diuretic therapy in the preceding month

Hypertrophic Cardiomyopathy

  • Established diagnosis of hypertrophic cardiomyopathy
  • Left ventricular wall thickness ≥15mm in any segment
  • Repolarisation abnormalities on 12-lead electrocardiogram NHYA class I-III heart failure, with stable symptoms not requiring change to diuretic therapy in the preceding month

Exclusion Criteria:

  • have a positive pregnancy test
  • women who are breast feeding
  • received an investigational drug or device within 30 days prior to administration of Mangafodipir
  • have known hypersensitivity to ondansetron or other selective serotonin 5-HT3 receptor blockers
  • have a history of ongoing drug abuse or alcoholism
  • have a history of torsades or prolonged QT/QTc interval
  • atrioventricular block (1st, 2nd or 3rd degree)
  • atrial fibrillation or flutter
  • have NYHA Grade IV heart failure
  • have abnormal liver function tests or a history of liver disease
  • have a baseline eGFR (estimated glomerular filtration rate) of <30 mL/min)
  • have uncontrolled hypertension
  • have any contraindications to MRI, including implanted devices/pacemakers
  • be maintained on either a calcium channel blocker or digoxin
  • known diagnosis of phaeochromocytoma

Additionally, cohort-specific exclusion criteria as follows:

Hypertrophic Cardiomyopathy

  • Coronary artery stenosis >50% any vessel
  • Previous myocardial infarction
  • Previous alcohol septal ablation
  • Moderate or severe aortic stenosis (mean gradient >25 mmHg, mean AVA ≤1.5 cm2 or peak velocity ≥3 m/sec),

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03607669

Layout table for location contacts
Contact: Nicholas B Spath 0131 242 6515 nick.spath@ed.ac.uk
Contact: Sponsor Representative 0131 242 3330 enquiries@accord.scot

Layout table for location information
United Kingdom
Queen's Medical Research Institute, University of Edinburgh Recruiting
Edinburgh, Midlothian, United Kingdom, EH16 4TJ
Contact: Nicholas B Spath, MBBS BSc    0131 242 6515    nick.spath@ed.ac.uk   
Sponsors and Collaborators
University of Edinburgh
Layout table for investigator information
Study Director: David E Newby, MD PhD University of Edinburgh
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University of Edinburgh
ClinicalTrials.gov Identifier: NCT03607669    
Other Study ID Numbers: AC16109
First Posted: July 31, 2018    Key Record Dates
Last Update Posted: July 31, 2018
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiomyopathy, Hypertrophic
Cardiomyopathy, Dilated
Heart Diseases
Cardiovascular Diseases
Aortic Stenosis, Subvalvular
Aortic Valve Stenosis
Aortic Valve Disease
Heart Valve Diseases
Genetic Diseases, Inborn